Hyperlipidemia Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc

"The new report published by The Business Research Company, titled Hyperlipidemia Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the hyperlipidemia market size has grown steadily in recent years. It will grow from $19.41 billion in 2023 to $20.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $23.25 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Heart Disease
Increasing incidences of chronic disorders such as heart disease are expected to propel the growth of the hyperlipidemia market going forward. Heart diseases refer to diseases that affect the heart and its functioning. Hyperlipidemia treatment helps people suffering from heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function and reducing the need for invasive interventions. For instance, in March 2022, according to a report published by The Office for National Statistics, a UK-based government department, the number of deaths due to heart attacks increased from 19,440 in 2020 to 20,061 in 2021. Therefore, increasing incidences of chronic disorders such as heart disease drive the growth of the hyperlipidemia market.

Innovative Products Drive Competitive Advantage For Leading Companies In The Hyperlipidemia Market
Major companies operating in the hyperlipidemia market are focused on developing innovative products, such as advanced lipid-lowering therapies, to sustain their position in the market. For example, in December 2021, Novartis, a US-based pharmaceutical company, launched a new hyperlipidemia drug called Leqvio (inclisiran), approved by the Food and Drug Administration, a US-based government agency. This is the first-in-class siRNA (small interfering RNA) drug that is used to lower cholesterol as an adjunct treatment to diet and statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

The hyperlipidemia market covered in this report is segmented -

1) By Type: Familial; Acquired
2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12873&type=discount

Major players in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

Contents of the report:
1. Executive Summary
2. Hyperlipidemia Market Report Structure
3. Hyperlipidemia Market Trends And Strategies
4. Hyperlipidemia Market - Macro Economic Scenario
5. Hyperlipidemia Market Size And Growth
…..
27. Hyperlipidemia Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.